<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196104</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-TI-162</org_study_id>
    <nct_id>NCT01196104</nct_id>
  </id_info>
  <brief_title>Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler</brief_title>
  <official_title>A Phase 3b, Multicenter, Open-label, Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder, Using the Gen2 Inhaler, in Combination With Insulin Glargine Versus Insulin Aspart in Combination With Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Over a 16-week Treatment Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mannkind Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, forced-titration clinical trial evaluating the efficacy
      and safety of Technosphere Insulin (TI) Inhalation Powder in combination with insulin
      glargine versus insulin aspart in combination with insulin glargine in subjects with type 2
      diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 3 clinical trial is designed to examine the efficacy and safety of inhaled prandial TI
      Inhalation Powder in combination with basal insulin verses insulin aspart in combination with
      basal insulin in subjects with type 2 diabetes who are suboptimally controlled with their
      current insulin regimens.This trial will employ a variety of methods to intensively manage
      these subjects.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    For Business Reasons
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c (%) From Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Change from Baseline in glycated hemoglobin at Week 16</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Effect of Each Treatment on HbA1c</measure>
    <time_frame>Change from baseline to 16 weeks</time_frame>
    <description>Not analyzed due to early termination of the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Fasting Plasma Glucose (FPG) Levels at Randomization and Throughout the Study</measure>
    <time_frame>Change from baseline to 16 weeks</time_frame>
    <description>Not analyzed due to early termination of the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Post-prandial Glucose (PPG) Levels at Randomization and Throughout the Study</measure>
    <time_frame>Change from baseline to 16 weeks</time_frame>
    <description>Not analyzed due to early termination of the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycomark and Fructosamine Levels Measured Throughout the Study</measure>
    <time_frame>Change from baseline to 16 weeks</time_frame>
    <description>Not analyzed due to early termination of the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seven-point Glucose at Randomization and Throughout the Study</measure>
    <time_frame>Change from baseline to 16 weeks</time_frame>
    <description>Not analyzed due to early termination of the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Excursions and Variability as Assessed Through Continuous Glucose Monitoring (CGM)</measure>
    <time_frame>Change from baseline to 16 weeks</time_frame>
    <description>Not analyzed due to early termination of the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Body Weight at 16 Weeks</measure>
    <time_frame>Change from baseline to 16 weeks</time_frame>
    <description>Not analyzed due to early termination of the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction as Assessed by Subject Treatment and Health Outcomes Questionnaires</measure>
    <time_frame>Change from baseline to 16 weeks</time_frame>
    <description>Not analyzed due to early termination of the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Cough Episodes</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Total number of times patients coughed once, intermittently or continuously (inclusive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Hypoglycemic Event Rate</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Severe hypoglycemic event rate, ie, total number of events divided by subject-months of observation
Severe hypoglycemia is defined as a subject who requires the assistance of another individual (not merely requested) and either:
SMBG levels ≤ 36 mg/dL OR
There is a prompt response to the administration of carbohydrate, glucagon, or other resuscitative measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mild or Moderate Hypoglycemic Event Rate</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Mild or moderate hypoglycemic event rate, ie, total number of events divided by subject-months of observation
Nonsevere hypoglycemia is defined as a subject:
SMBG levels &lt; 70 mg/dL AND/OR
Symptoms that are relieved by the self-administration of carbohydrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Cough Episodes</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Number of Subjects Reporting Cough Episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Intermittent Coughing Episodes</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Number of subjects reporting Intermittent Coughing Episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Single Coughing Episodes</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Total number of times patients coughed only once</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cough Episodes Occuring Within 10 Minutes of Drug Inhalation</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Week 16 Forced Expiratory Volume in 1 Second</measure>
    <time_frame>Week 16</time_frame>
    <description>Week 16 FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Week 16 Change From Baseline in Forced Expiratory Volume in 1 Second</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Week 16 Change from Baseline in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Week 20 (Follow-up) Forced Expiratory Volume in 1 Second</measure>
    <time_frame>Week 20 (Follow-up)</time_frame>
    <description>Week 20 (Follow-up) FEV1, 4 weeks after discontinuation of study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Week 20 (Follow-up) Change From Baseline in Forced Expiratory Volume in 1 Second</measure>
    <time_frame>Baseline to Week 20</time_frame>
    <description>Week 20 (Follow-up, 4 weeks after discontinuation of study treatment) Change from Baseline in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Week 16 Forced Vital Capacity</measure>
    <time_frame>Week 16</time_frame>
    <description>Week 16 FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Week 16 Change From Baseline Forced Vital Capacity</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Week 16 Change from Baseline FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Week 20 (Follow-up) Forced Vital Capacity</measure>
    <time_frame>Week 20</time_frame>
    <description>Week 20 (Follow-up, 4 weeks after discontinuation of study treatment) FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Week 20 (Follow-up) Change From Baseline in Forced Vital Capacity</measure>
    <time_frame>Baseline to Week 20</time_frame>
    <description>Week 20 (Follow-up, 4 weeks after discontinuation of study treatment) Change from Baseline in FVC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Technosphere® Insulin Inhalation Powder (TI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Glargine and Technosphere® Insulin Inhalation Powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Glargine and Insulin Aspart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere® Insulin Inhalation Powder</intervention_name>
    <arm_group_label>Technosphere® Insulin Inhalation Powder (TI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>Usual Care</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <arm_group_label>Technosphere® Insulin Inhalation Powder (TI)</arm_group_label>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥ 18 and ≤ 80 years of age

          -  Clinical diagnosis of type 2 diabetes mellitus for more than 12 months

          -  Body mass index (BMI) ≤ 45 kg/m2

          -  Glycated Hemoglobin (HbA1c) &gt; 6.5% and ≤ 10.0%

          -  Treatment with 1 to 3 Oral Antidiabetic Drugs (OADs) and basal insulin for a minimum
             of 3 months before screening. Doses of OADs must have been stable for 3 months before
             study entry

          -  Nonsmokers (includes cigarettes, cigars, pipes, and chewing tobacco) for the preceding
             ≥ 6 months

          -  Office spirometry at the investigator site

               -  Forced expiratory volume in 1 second (FEV1) ≥ 65% Third National Health and
                  Nutrition Examination Survey (NHANES III) predicted

               -  Forced vital capacity (FVC) ≥ 65% NHANES III predicted

               -  Forced expiratory volume in 1 second as a percentage of forced vital capacity
                  (FEV1/FVC) ≥ lower limit of normal (LLN)

        Exclusion criteria:

          -  Current or prior treatment with prandial or PreMix (70/30) insulin

          -  History of insulin pump use within 6 weeks of Visit 1

          -  Treatment with Glucagon-like Peptide (GLP-1) analog drugs within the preceding 12
             weeks of Visit 1

          -  History of chronic obstructive pulmonary disease (COPD), asthma, or any other
             clinically important pulmonary disease (eg, pulmonary fibrosis)

          -  Any clinically significant radiological findings on screening chest x-ray

          -  Use of medications for asthma, COPD, or any other chronic respiratory conditions

          -  Evidence of serious complications of diabetes (eg, symptomatic autonomic neuropathy)

          -  Significant cardiovascular dysfunction or history within 3 months of Visit 1 (eg,
             congestive heart failure [New York Heart Association {NYHA} Class III or IV])

          -  Serious arrhythmia, myocardial infarction, cardiac surgery, recurrent syncope,
             transient ischemic attacks, or any cerebrovascular accident

          -  History of pulmonary embolism or deep venous thrombosis in the 12 months before
             Screening (Visit 1)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Coastal Clinical Research Inc</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Research</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Care Partners Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laureate Clinical Research Group</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Pharmaceutical Research Center</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John H Stoger Jr Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LaPorte County Institute for Clinical Research Inc.</name>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc (Minneapolis)</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amin Radparvar's Private Practice</name>
      <address>
        <city>St Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic Research Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton Diabetes Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico HCS</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Diabetes and Endocrine Associates</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine Research Physicians East PA</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Your Diabetes Endocrine Nutrition Group, Inc.</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Clinical Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Diabetes Center Research Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Endocrine Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes &amp; Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAM Clinical Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Exodus Healthcare Network</name>
      <address>
        <city>Magna</city>
        <state>Utah</state>
        <zip>84044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Research Center -Fletcher Allen Health Care</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <results_first_submitted>July 22, 2014</results_first_submitted>
  <results_first_submitted_qc>October 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2014</results_first_posted>
  <disposition_first_submitted>May 9, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 9, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 14, 2012</disposition_first_posted>
  <last_update_submitted>October 21, 2014</last_update_submitted>
  <last_update_submitted_qc>October 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The FIrst Patient First Visit (FPFV) was September 21, 2010, and Last Patient Last Visit (LPLV) was August 25, 2011. Trial conducted in US. The study was terminated before completion of full enrollment for business reasons. Subjects already enrolled were allowed to complete the study to assess the safety of the titration algorithms.</recruitment_details>
      <pre_assignment_details>After a 1 week to 5 week run-in period, subjects were randomized to receive either TI Inhalation Powder in combination with insulin glargine, or insulin aspart in combination with insulin glargine.
105 Screened/46 Eligible. 39 subjects were randomized; 59 screen failures and 7 were screened but not randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Technosphere Insulin + Insulin Glargine</title>
          <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
        </group>
        <group group_id="P2">
          <title>Insulin Aspart + Insulin Glargine</title>
          <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Various</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Technosphere Insulin + Insulin Glargine</title>
          <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
        </group>
        <group group_id="B2">
          <title>Insulin Aspart + Insulin Glargine</title>
          <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" spread="7.95" lower_limit="47" upper_limit="72"/>
                    <measurement group_id="B2" value="58.1" spread="10.67" lower_limit="42" upper_limit="78"/>
                    <measurement group_id="B3" value="59.4" lower_limit="42" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.6" spread="7.95" lower_limit="3.7" upper_limit="35.9"/>
                    <measurement group_id="B2" value="15.6" spread="10.67" lower_limit="2.5" upper_limit="43.1"/>
                    <measurement group_id="B3" value="15.1" lower_limit="2.5" upper_limit="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <description>Body Weight (kg) at Randomization</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100.9" spread="21.84" lower_limit="54.1" upper_limit="141.9"/>
                    <measurement group_id="B2" value="100.8" spread="20.30" lower_limit="66.4" upper_limit="138.6"/>
                    <measurement group_id="B3" value="100.9" lower_limit="54.1" upper_limit="141.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body Mass Index (kg/m2) at Randomization</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="5.78" lower_limit="19.3" upper_limit="42.9"/>
                    <measurement group_id="B2" value="33.3" spread="5.51" lower_limit="24.3" upper_limit="44.1"/>
                    <measurement group_id="B3" value="33.2" lower_limit="19.3" upper_limit="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <description>HbA1c (%) at randomization (NOTE: Aspart group only had 17 with HbA1c measurements at baseline)</description>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.76" spread="1.097" lower_limit="6.3" upper_limit="10.2"/>
                    <measurement group_id="B2" value="7.94" spread="1.098" lower_limit="6.7" upper_limit="10.3"/>
                    <measurement group_id="B3" value="7.85" lower_limit="6.3" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c (%) From Baseline to Week 16</title>
        <description>Change from Baseline in glycated hemoglobin at Week 16</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Safety Population, participants with data available at Baseline and Week 16</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c (%) From Baseline to Week 16</title>
          <description>Change from Baseline in glycated hemoglobin at Week 16</description>
          <population>Safety Population, participants with data available at Baseline and Week 16</population>
          <units>Percentage of total hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2179" spread="0.1468"/>
                    <measurement group_id="O2" value="-1.2652" spread="0.1571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA model with terms of treatment as a fixed effect and baseline HbA1c as covariate</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Study terminated early due to business reasons, results are not properly powered.</non_inferiority_desc>
            <p_value>0.8283</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0473</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2158</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4901</ci_lower_limit>
            <ci_upper_limit>0.3956</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Effect of Each Treatment on HbA1c</title>
        <description>Not analyzed due to early termination of the trial.</description>
        <time_frame>Change from baseline to 16 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Fasting Plasma Glucose (FPG) Levels at Randomization and Throughout the Study</title>
        <description>Not analyzed due to early termination of the trial.</description>
        <time_frame>Change from baseline to 16 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Post-prandial Glucose (PPG) Levels at Randomization and Throughout the Study</title>
        <description>Not analyzed due to early termination of the trial.</description>
        <time_frame>Change from baseline to 16 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycomark and Fructosamine Levels Measured Throughout the Study</title>
        <description>Not analyzed due to early termination of the trial.</description>
        <time_frame>Change from baseline to 16 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seven-point Glucose at Randomization and Throughout the Study</title>
        <description>Not analyzed due to early termination of the trial.</description>
        <time_frame>Change from baseline to 16 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemic Excursions and Variability as Assessed Through Continuous Glucose Monitoring (CGM)</title>
        <description>Not analyzed due to early termination of the trial.</description>
        <time_frame>Change from baseline to 16 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Body Weight at 16 Weeks</title>
        <description>Not analyzed due to early termination of the trial.</description>
        <time_frame>Change from baseline to 16 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Satisfaction as Assessed by Subject Treatment and Health Outcomes Questionnaires</title>
        <description>Not analyzed due to early termination of the trial.</description>
        <time_frame>Change from baseline to 16 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Cough Episodes</title>
        <description>Total number of times patients coughed once, intermittently or continuously (inclusive)</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Cough Episodes</title>
          <description>Total number of times patients coughed once, intermittently or continuously (inclusive)</description>
          <population>Safety Population</population>
          <units>Cough episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Hypoglycemic Event Rate</title>
        <description>Severe hypoglycemic event rate, ie, total number of events divided by subject-months of observation
Severe hypoglycemia is defined as a subject who requires the assistance of another individual (not merely requested) and either:
SMBG levels ≤ 36 mg/dL OR
There is a prompt response to the administration of carbohydrate, glucagon, or other resuscitative measures</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Hypoglycemic Event Rate</title>
          <description>Severe hypoglycemic event rate, ie, total number of events divided by subject-months of observation
Severe hypoglycemia is defined as a subject who requires the assistance of another individual (not merely requested) and either:
SMBG levels ≤ 36 mg/dL OR
There is a prompt response to the administration of carbohydrate, glucagon, or other resuscitative measures</description>
          <population>Safety Population</population>
          <units>Events / subject-month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mild or Moderate Hypoglycemic Event Rate</title>
        <description>Mild or moderate hypoglycemic event rate, ie, total number of events divided by subject-months of observation
Nonsevere hypoglycemia is defined as a subject:
SMBG levels &lt; 70 mg/dL AND/OR
Symptoms that are relieved by the self-administration of carbohydrates</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere® Insulin Inhalation Powder (TI)</title>
            <description>Insulin Glargine and Technosphere® Insulin Inhalation Powder
Technosphere® Insulin Inhalation Powder
Insulin Glargine</description>
          </group>
          <group group_id="O2">
            <title>Comparator</title>
            <description>Insulin Glargine and Insulin Aspart
Insulin Aspart: Usual Care
Insulin Glargine</description>
          </group>
        </group_list>
        <measure>
          <title>Mild or Moderate Hypoglycemic Event Rate</title>
          <description>Mild or moderate hypoglycemic event rate, ie, total number of events divided by subject-months of observation
Nonsevere hypoglycemia is defined as a subject:
SMBG levels &lt; 70 mg/dL AND/OR
Symptoms that are relieved by the self-administration of carbohydrates</description>
          <population>Safety Population</population>
          <units>Events / subject-month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47"/>
                    <measurement group_id="O2" value="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Cough Episodes</title>
        <description>Number of Subjects Reporting Cough Episodes</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Cough Episodes</title>
          <description>Number of Subjects Reporting Cough Episodes</description>
          <population>Safety Population</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Intermittent Coughing Episodes</title>
        <description>Number of subjects reporting Intermittent Coughing Episodes</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Intermittent Coughing Episodes</title>
          <description>Number of subjects reporting Intermittent Coughing Episodes</description>
          <population>Safety Population</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Single Coughing Episodes</title>
        <description>Total number of times patients coughed only once</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Single Coughing Episodes</title>
          <description>Total number of times patients coughed only once</description>
          <population>Safety Population</population>
          <units>Cough episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cough Episodes Occuring Within 10 Minutes of Drug Inhalation</title>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cough Episodes Occuring Within 10 Minutes of Drug Inhalation</title>
          <population>Safety Population</population>
          <units>Cough episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Baseline FEV1</description>
        <time_frame>Baseline</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Baseline FEV1</description>
          <population>Safety Population</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="0.63"/>
                    <measurement group_id="O2" value="2.83" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Week 16 Forced Expiratory Volume in 1 Second</title>
        <description>Week 16 FEV1</description>
        <time_frame>Week 16</time_frame>
        <population>Safety Population, with data available at Week 16</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Week 16 Forced Expiratory Volume in 1 Second</title>
          <description>Week 16 FEV1</description>
          <population>Safety Population, with data available at Week 16</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="0.57"/>
                    <measurement group_id="O2" value="2.66" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Week 16 Change From Baseline in Forced Expiratory Volume in 1 Second</title>
        <description>Week 16 Change from Baseline in FEV1</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Safety Population, with data available at Week 16</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Week 16 Change From Baseline in Forced Expiratory Volume in 1 Second</title>
          <description>Week 16 Change from Baseline in FEV1</description>
          <population>Safety Population, with data available at Week 16</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.32"/>
                    <measurement group_id="O2" value="-0.07" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Week 20 (Follow-up) Forced Expiratory Volume in 1 Second</title>
        <description>Week 20 (Follow-up) FEV1, 4 weeks after discontinuation of study treatment</description>
        <time_frame>Week 20 (Follow-up)</time_frame>
        <population>Safety Population, with data available at Week 20</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Week 20 (Follow-up) Forced Expiratory Volume in 1 Second</title>
          <description>Week 20 (Follow-up) FEV1, 4 weeks after discontinuation of study treatment</description>
          <population>Safety Population, with data available at Week 20</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.07" spread="0.55"/>
                    <measurement group_id="O2" value="2.86" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Week 20 (Follow-up) Change From Baseline in Forced Expiratory Volume in 1 Second</title>
        <description>Week 20 (Follow-up, 4 weeks after discontinuation of study treatment) Change from Baseline in FEV1</description>
        <time_frame>Baseline to Week 20</time_frame>
        <population>Safety Population, with data available at Week 20</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Week 20 (Follow-up) Change From Baseline in Forced Expiratory Volume in 1 Second</title>
          <description>Week 20 (Follow-up, 4 weeks after discontinuation of study treatment) Change from Baseline in FEV1</description>
          <population>Safety Population, with data available at Week 20</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.29"/>
                    <measurement group_id="O2" value="-0.05" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Forced Vital Capacity (FVC)</title>
        <description>Baseline FVC</description>
        <time_frame>Baseline</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Forced Vital Capacity (FVC)</title>
          <description>Baseline FVC</description>
          <population>Safety Population</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" spread="0.78"/>
                    <measurement group_id="O2" value="3.48" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Week 16 Forced Vital Capacity</title>
        <description>Week 16 FVC</description>
        <time_frame>Week 16</time_frame>
        <population>Safety Population, with data available at Week 16</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Week 16 Forced Vital Capacity</title>
          <description>Week 16 FVC</description>
          <population>Safety Population, with data available at Week 16</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="0.72"/>
                    <measurement group_id="O2" value="3.33" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Week 16 Change From Baseline Forced Vital Capacity</title>
        <description>Week 16 Change from Baseline FVC</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Safety Population, with data available at Week 16</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Week 16 Change From Baseline Forced Vital Capacity</title>
          <description>Week 16 Change from Baseline FVC</description>
          <population>Safety Population, with data available at Week 16</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.34"/>
                    <measurement group_id="O2" value="-0.07" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Week 20 (Follow-up) Forced Vital Capacity</title>
        <description>Week 20 (Follow-up, 4 weeks after discontinuation of study treatment) FVC</description>
        <time_frame>Week 20</time_frame>
        <population>Safety Population, with data available at Week 20</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Week 20 (Follow-up) Forced Vital Capacity</title>
          <description>Week 20 (Follow-up, 4 weeks after discontinuation of study treatment) FVC</description>
          <population>Safety Population, with data available at Week 20</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="0.73"/>
                    <measurement group_id="O2" value="3.57" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Week 20 (Follow-up) Change From Baseline in Forced Vital Capacity</title>
        <description>Week 20 (Follow-up, 4 weeks after discontinuation of study treatment) Change from Baseline in FVC</description>
        <time_frame>Baseline to Week 20</time_frame>
        <population>Safety Population, with data available at Week 20</population>
        <group_list>
          <group group_id="O1">
            <title>Technosphere Insulin + Insulin Glargine</title>
            <description>Technosphere Insulin Inhalation Powder (administered prior to each meal) in combination with insulin glargine (once or twice daily); doses individualized for each patient</description>
          </group>
          <group group_id="O2">
            <title>Insulin Aspart + Insulin Glargine</title>
            <description>Insulin Aspart (prior to each meal) and Insulin Glargine (once or twice daily) ; doses individualized for each patient</description>
          </group>
        </group_list>
        <measure>
          <title>Week 20 (Follow-up) Change From Baseline in Forced Vital Capacity</title>
          <description>Week 20 (Follow-up, 4 weeks after discontinuation of study treatment) Change from Baseline in FVC</description>
          <population>Safety Population, with data available at Week 20</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.35"/>
                    <measurement group_id="O2" value="-0.06" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose to 30d post last dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Technosphere® Insulin Inhalation Powder (TI)</title>
          <description>Insulin Glargine and Technosphere® Insulin Inhalation Powder
Technosphere® Insulin Inhalation Powder
Insulin Glargine</description>
        </group>
        <group group_id="E2">
          <title>Comparator</title>
          <description>Insulin Glargine and Insulin Aspart
Insulin Aspart: Usual Care
Insulin Glargine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Mydriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA15.1">Blood Testosterone Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chest Wall Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Plantar Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dry Throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract Operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>- Early termination of trial leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>MannKind Corporation</organization>
      <phone>201-983-5000</phone>
      <email>aboss@mannkindcorp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

